Cargando…

Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand

PURPOSE: To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of reti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojanaporn, Duangnate, Attaseth, Taweevat, Dieosuthichat, Wimwipa, Leelawongs, Kitikul, Pakakasama, Samart, Anurathapan, Usanarat, Chanthanaphak, Ekachat, Singhara Na Ayudhaya, Sirintara, Aroonroch, Rangsima, Hongeng, Suradej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508219/
https://www.ncbi.nlm.nih.gov/pubmed/33005446
http://dx.doi.org/10.1155/2020/4231841
_version_ 1783585386426007552
author Rojanaporn, Duangnate
Attaseth, Taweevat
Dieosuthichat, Wimwipa
Leelawongs, Kitikul
Pakakasama, Samart
Anurathapan, Usanarat
Chanthanaphak, Ekachat
Singhara Na Ayudhaya, Sirintara
Aroonroch, Rangsima
Hongeng, Suradej
author_facet Rojanaporn, Duangnate
Attaseth, Taweevat
Dieosuthichat, Wimwipa
Leelawongs, Kitikul
Pakakasama, Samart
Anurathapan, Usanarat
Chanthanaphak, Ekachat
Singhara Na Ayudhaya, Sirintara
Aroonroch, Rangsima
Hongeng, Suradej
author_sort Rojanaporn, Duangnate
collection PubMed
description PURPOSE: To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of retinoblastoma patients who were treated at Ramathibodi Hospital, Bangkok, Thailand, between January 1, 2007, and December 31, 2018. The log-rank test was used to explore clinical characteristics and treatment modalities that affected globe salvage and survival curves. RESULTS: This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1–48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2–148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%. CONCLUSIONS: Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases.
format Online
Article
Text
id pubmed-7508219
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-75082192020-09-30 Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand Rojanaporn, Duangnate Attaseth, Taweevat Dieosuthichat, Wimwipa Leelawongs, Kitikul Pakakasama, Samart Anurathapan, Usanarat Chanthanaphak, Ekachat Singhara Na Ayudhaya, Sirintara Aroonroch, Rangsima Hongeng, Suradej J Ophthalmol Research Article PURPOSE: To investigate the clinical presentations and outcomes of retinoblastoma in relation to the advent of new multimodal treatments in Thailand. Patients and Methods. Retrospective case series. We evaluated the clinical presentation, staging, details of treatment, and treatment outcomes of retinoblastoma patients who were treated at Ramathibodi Hospital, Bangkok, Thailand, between January 1, 2007, and December 31, 2018. The log-rank test was used to explore clinical characteristics and treatment modalities that affected globe salvage and survival curves. RESULTS: This study included 124 eyes of 81 patients with retinoblastoma. Forty-three patients (53.1%) had bilateral retinoblastoma. The median age at diagnosis was 8 months (range, 1–48 months). Of 124 eyes, 9 eyes (7.3%) had extraocular retinoblastoma and 115 eyes (92.7%) had intraocular retinoblastoma, which were classified by the International Classification of Retinoblastoma (ICRB) as group A, 4 eyes (3.5%); group B, 19 eyes (16.5%); group C, 6 eyes (5.2%); group D, 31 eyes (27%); and group E, 56 eyes (47.8%). Treatment included systemic chemotherapy, intra-arterial chemotherapy, ruthenium-106 plaque brachytherapy, external beam radiation therapy, cryotherapy, transpupillary thermotherapy, subtenon chemotherapy, and intravitreal chemotherapy. At the median follow-up period of 38.4 months (range, 0.2–148.2 months), the overall globe salvage rate of intraocular retinoblastoma was 51.7%. For unilateral retinoblastoma, globe salvage rate was 37.5% (group B, 100%; group C, 100%; group D, 50%; and group E, 18.8%). For bilateral intraocular retinoblastoma, the globe salvage rate was 57.8% (group A, 100 %; group B, 94.4%; group C, 100%; group D, 64.7%; and group E, 28.2%). The overall survival rate was 93.8%. CONCLUSIONS: Recent advanced treatment modalities have improved the probability of globe salvage. However, enucleation remains an important life-saving intervention in many advanced cases. Hindawi 2020-09-10 /pmc/articles/PMC7508219/ /pubmed/33005446 http://dx.doi.org/10.1155/2020/4231841 Text en Copyright © 2020 Duangnate Rojanaporn et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rojanaporn, Duangnate
Attaseth, Taweevat
Dieosuthichat, Wimwipa
Leelawongs, Kitikul
Pakakasama, Samart
Anurathapan, Usanarat
Chanthanaphak, Ekachat
Singhara Na Ayudhaya, Sirintara
Aroonroch, Rangsima
Hongeng, Suradej
Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
title Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
title_full Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
title_fullStr Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
title_full_unstemmed Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
title_short Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand
title_sort clinical presentations and outcomes of retinoblastoma patients in relation to the advent of new multimodal treatments: a 12-year report from single tertiary referral institute in thailand
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508219/
https://www.ncbi.nlm.nih.gov/pubmed/33005446
http://dx.doi.org/10.1155/2020/4231841
work_keys_str_mv AT rojanapornduangnate clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT attasethtaweevat clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT dieosuthichatwimwipa clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT leelawongskitikul clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT pakakasamasamart clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT anurathapanusanarat clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT chanthanaphakekachat clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT singharanaayudhayasirintara clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT aroonrochrangsima clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand
AT hongengsuradej clinicalpresentationsandoutcomesofretinoblastomapatientsinrelationtotheadventofnewmultimodaltreatmentsa12yearreportfromsingletertiaryreferralinstituteinthailand